Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2021 | Beyond BCMA: GPRC5D & FcRH5

Nikhil Munshi • 5 May 2021
IMS 2021
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Loss of B-cell maturation antigen (BCMA) poses a large challenge, with many newer therapies having this target. Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, explains how this issue is being addressed with research, and where believes the science will take us. Specifically mentioned is the targeting of GPRC5D, FcRH5, and the use of combinatorial approaches. This interview took place during the 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA.

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:02
Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals